NOV 09, 2017 | ALYSSA B. CHRISTENSEN, PHARMD, AND VIKTORIJA O. BARR, PHARMD, BCPS-AQ ID
Studying the impact of antibiotics for sepsis is difficult due to the multiple confounding factors, such as severity of illness, time to diagnosis, length of stay, and availability of adequate control groups. Current evidence suggests that antibiotic selection for sepsis can have a severe impact on the rate of CDIs. Vancomycin and piperacillin/tazobactam appear to be low-risk antibiotics for the development of CDIs, whereas cephalosporins and fluoroquinolones carry a much greater risk. Use of BSAs for sepsis requires a delicate balance between appropriate empiric therapy and prevention of CDIs. Further studies are needed to quantify the risks associated with antibiotic use in sepsis, identify patients at greatest risk of CDIs, and establish effective de-escalation practices.
Dr. Christensen is a clinical assistant professor at the University of Illinois at Chicago, Illinois, and an infectious diseases pharmacist at OSF Saint Anthony Medical Center. She earned her PharmD from Rosalind Franklin University, completed a PGY-1 pharmacy practice residency at Legacy Health, and a PGY-2 infectious diseases residency at Northwestern Memorial Hospital. She is an active member of SIDP.
Dr. Barr is an assistant professor of pharmacy practice at Rosalind Franklin University North Chicago, Illinois and practices at Northwestern Memorial Hospital Chicago. She earned her doctor of pharmacy degree at Drake University College of Pharmacy. She completed her PGY- 1 pharmacy practice residency at Parkview Health and her PGY- 2 infectious diseases residency at the Detroit Medical Center. She is an active member of SIDP.
- Desai K, Gupta SB, Dubberke ER, Prabhu VS, Browne C, Mast TC. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis. 2016;16:303. doi: 10.1186/s12879-016-1610-3.
- Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254-1260. doi: 10.1086/496986.
- Jobe BA, Grasley A, Deveney KE, Deveney CW, Sheppard BC. Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg. 1995;169(5):480-483. doi: 10.1016/S0002-9610(99)80199-8.
- Hiensch R, Poeran J, Saunders-Hao P, et al. Impact of an electronic sepsis initiative on antibiotic use and health care facility-onset Clostridium difficile infection rates [published online June 8, 2017]. Am J Infect. Control. doi: 10.1016/j.ajic.2017.04.005.
- Gravel D, Miller M, Simor A, et al; Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis. 2009;48(5):568-576. doi: 10.1086/596703.
- Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007;13(9):1417-1419. doi: 10.3201/eid1309.061116.
- Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079-1084. doi: 10.1016/S0140-6736(05)67420-X.
- Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353(23):2442-2449. doi: 10.1056/NEJMoa051639.
- Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents. 2016;48(1):1-10. doi: 10.1016/j.ijantimicag.2016.03.008.
- Brown K, Valenta K, Fisman D, Simor A, Daneman N. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med. 2015;175(4):626-633. doi: 10.1001/jamainternmed.2014.8273.
- Dubberke ER, Yan Y, Reske KA, et al. Development and validation of a Clostridium difficile infection risk prediction model. Infect Control Hosp Epidemiol. 2011;32(4):360-366. doi: 10.1086/658944.
- Hecht JR, Olinger EJ. Clostridium difficile colitis secondary to intravenous vancomycin. Dig. Dis. Sci. 1989;34(1):148-149.
- Changela U, Cannon JP, Aneziokoro C, Shah PS, Thottapurathu L, Lentino J. Risk factors and mortality associated with Clostridium difficile-associated diarrhoea at a VA hospital. Int J Antimicrob Agents. 2004;24(6):562-566. doi: 10.1016/j.ijantimicag.2004.07.011.
- Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2005;49(8):3513-3516. doi: 10.1128/AAC.49.8.3513-3516.2005.
- Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother. 2014;69(4):881-891. doi: 10.1093/jac/dkt477.
- Flaherty SK, Weber RL, Chase M, et al. Septic shock and adequacy of early empiric antibiotics in the emergency department. J Emerg Med. 2014;47(5):601-607. doi: 10.1016/j.jemermed.2014.06.037.
- Kundrapu S, Sunkesula VC, Jury LA, et al. Do piperacillin/tazobactam and other antibiotics with inhibitory activity against Clostridium difficile reduce the risk for acquisition of C. difficile colonization? BMC Infec. Dis. 2016;16:159. doi: 10.1186/s12879-016-1514-2.
- Gross AE, Johannes RS, Gupta V, Tabak YP, Srinivasan A, Bleasdale SC. The effect of a piperacillin/tazobactam shortage on antimicrobial prescribing and Clostridium difficile risk in 88 U.S. medical centers. Clin Infect Dis. 2017. doi: 10.1093/cid/cix379.
- Mendez MN, Gibbs L, Jacobs RA, McCulloch CE, Winston L, Guglielmo BJ. Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant Enterococci and Clostridium difficile Infections. Pharmacotherapy. 2006;26(1):61-67. doi:10.1592/phco.2006.26.1.61.
- McCusker ME, Harris AD, Perencevich E, Roghmann MC. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003;9(6):730-733. doi: 10.3201/eid0906.020385.
- Valiquette L, Cossette B, Garant MP, Diab H, Pepin J. Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1/027 strain. Clin Infec. Dis. 2007;45(suppl 2):S112-S121. doi: 10.1086/519258.
- Talpaert MJ, Gopal Rao G, Cooper BS, Wade P. Impact of guidelines and enhanced antibiotic stewardship on reducing broad-spectrum antibiotic usage and its effect on incidence of Clostridium difficile infection. J Antimicrob Chemother. 2011;66(9):2168-2174. doi: 10.1093/jac/dkr253.
- Lagu T, Stefan MS, Haessler S, et al. The impact of hospital-onset Clostridium difficile infection on outcomes of hospitalized patients with sepsis. J Hosp Med. 2014;9(7):411-417. doi: 10.1002/jhm.2199.
- Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.
- Bernard GR, Vincent JL, Laterre PF, et al; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344(10):699-709. doi: 10.1056/NEJM200103083441001.
- Garnacho-Montero J, Gutierrez-Pizarraya A, Escoresca-Ortega A, et al. De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock. Intensive Care Med. 2014;40(1):32-40. doi: 10.1007/s00134-013-3077-7.
- Heenen S, Jacobs F, Vincent JL. Antibiotic strategies in severe nosocomial sepsis: why do we not de-escalate more often? Crit Care Med. 2012;40(5):1404-1409. doi: 10.1097/CCM.0b013e3182416ecf.